FLOT1 and head and neck squamous cell carcinoma: As shown in Supplementary Fig. 3A, B the FLOT1-HR subgroup was associated with poorer OS and RFS compared to the FLOT1-LR subgroup in HNSCC patients receiving chemoradiotherapy (OS: 43.8% vs. 84.6% at 5 years, P = 0.0016; RFS: 28.6% vs. 79.4% at 5 years, P = 0.0054, respectively) Additionally, as depicted in Fig. 3C, D the FLOT1-HR subgroup showed worse OS and RFS outcomes in patients receiving only RT compared to the FLOT1-LR subgroup.